Study discussed how injury and abnormal repair of the airway epithelium drive chronic obstructive pulmonary disease (COPD) and asthma.
Incannex Healthcare : Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL 42X Form 8 K | Psychedelic Invest
NEW YORK, USA and MELBOURNE, Australia, 30 July, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company